The partnership combines Dark Horse's regulatory and development consulting with KunTuo's on-the-ground clinical trial execution to help companies launch studies faster and generate data to support regulatory submissions.
The Phase 1 cord blood-derived stem cell therapy for sacroiliac joint-related lower back pain showed an encouraging early safety profile and symptom improvement, supporting plans to begin Phase 2 later this year.
The trial demonstrated that Cartistem can both relieve symptoms and regenerate cartilage, and the company is advancing manufacturing readiness for its first overseas commercialization move.
Cellares said its automated Cell Shuttle platform successfully produced GMP-compliant rese-cel doses for Cabaletta Bio’s RESET trial, marking an early proof point that automation can help lower costs and scale autologous CAR...
The Gibco CTS DynaXS Single Use Bioreactor is designed to help cell therapy developers scale from process development to cGMP-ready clinical manufacturing with greater flexibility, process control, and support for diverse applications...
Cellular Intelligence will use its AI platform to speed the clinical development and scalable manufacturing of a Phase 1/2 stem cell-derived Parkinson’s therapy acquired from Novo Nordisk, which also took an equity...
Trailhead Biosystems has launched a functionally validated, highly pure iPSC-derived endothelial cell product designed to give researchers a scalable, reproducible human vascular model for angiogenesis, inflammation, drug screening and toxicity studies.
The funding will support Latus Bio’s lead gene therapy programs in Huntington’s and CLN2 disease while advancing its low-dose AAV delivery platform designed to make gene therapies safer, more scalable, and accessible...
The company is evaluating whether Cellular Origins’ Constellation automation platform can be used in selected Immatics manufacturing steps to improve consistency, efficiency, and scalability for next-generation cancer cell therapies.
A phase 2 trial found that adding a lab-expanded stem cell product made from multiple pooled cord blood donors to a single cord blood transplant may broaden access to transplants for leukemia...
